Cumulative incidence of femoral localized periosteal thickening (beaking) preceding atypical femoral fractures in patients with rheumatoid arthritis

被引:6
作者
Sato, H. [1 ,2 ]
Takai, C. [1 ]
Kondo, N. [3 ]
Kurosawa, Y. [4 ]
Hasegawa, E. [4 ]
Wakamatsu, A. [4 ]
Kobayashi, D. [4 ]
Nakatsue, T. [4 ]
Abe, A. [1 ]
Ito, S. [1 ]
Ishikawa, H. [1 ]
Kazama, J. J. [5 ]
Kuroda, T. [2 ]
Suzuki, Y. [2 ]
Endo, N. [6 ]
Narita, I [4 ]
机构
[1] Niigata Rheumat Ctr, Dept Rheumatol, 1-2-8 Honcho, Shibata 9570054, Japan
[2] Niigata Univ, Hlth Adm Ctr, Nishi Ku, 2-8050 Ikarashi, Niigata 9502181, Japan
[3] Niigata Univ, Div Orthoped Surg, Grad Sch Med & Dent Sci, Chuo Ku, 1-757 Asahimachi Dori, Niigata 9518510, Japan
[4] Niigata Univ, Div Clin Nephrol & Rheumatol, Grad Sch Med & Dent Sci, Chuo Ku, 1-757 Asahimachi Dori, Niigata 9518510, Japan
[5] Fukushima Med Univ, Dept Nephrol & Hypertens, 1 Hikariga Oka, Fukushima 9601295, Japan
[6] Tsubame Rosai Hosp, Div Orthoped Surg, 633 Sawatari, Tsubame 9591228, Japan
关键词
Atypical femoral fracture; Beaking; Bisphosphonate; Femoral localized periosteal thickening; Glucocorticoid; Rheumatoid arthritis; LONG-TERM GLUCOCORTICOIDS; BISPHOSPHONATE THERAPY; AUTOIMMUNE-DISEASES; FEMUR FRACTURES; RISK-FACTORS; METHOTREXATE; WOMEN;
D O I
10.1007/s00198-020-05601-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incidence of localized periosteal thickening (LPT, also termed beaking) of the lateral cortex that often precedes an atypical femoral fracture (AFF) was not high in patients with rheumatoid arthritis (RA) but incomplete AFFs developed in two patients. Higher-dose prednisolone was a significant risk factor for LPT in patients with RA. Introduction Atypical femoral fractures (AFFs) are stress fractures; bisphosphonate (BP) use is a major risk factor for the development of such fractures. Localized periosteal thickening (LPT, also termed beaking) of the lateral cortex often precedes a complete or incomplete AFF. We evaluated the incidence of latent LPT in patients with rheumatoid arthritis (RA), to evaluate LPT progression, and to define LPT risk factors. Methods A total of 254 patients with RA were included; all underwent annual X-ray evaluation, dual-energy X-ray absorptiometry, and analyses of serum and bone metabolic markers for 2-3 years. LPT of the lateral cortex was sought in femoral X-rays. Results The incidence of LPT was 2.4% (6/254). Among patients on both BP and prednisolone (PSL) at enrollment, the incidence was 2.3% (3/131). Two femurs of two patients with LPT developed incomplete AFFs; LPT was extensive and associated with endosteal thickening. One patient had been on BP and PSL and microscopic polyangiitis was comorbidity. The other was on a selective estrogen receptor modulator and PSL. A daily PSL dose >5 mg (OR 11.4; 95%CI 2.15-60.2;p = 0.004) and higher-dose methotrexate (OR 1.22; 95%CI 1.01-1.49;p = 0.043) were significant risk factors for LPT. Conclusions The incidence of latent LPT was not high (2.4%) but incomplete AFFs developed in two RA patients. Higher-dose PSL because of a comorbid disease requiring glucocorticoid treatment other than RA or refractory RA were risk factors for LPT; X-ray screening for latent LPT would usefully prevent complete AFFs.
引用
收藏
页码:363 / 375
页数:13
相关论文
共 32 条
[1]   Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research [J].
Adler, Robert A. ;
El-Hajj Fuleihan, Ghada ;
Bauer, Douglas C. ;
Camacho, Pauline M. ;
Clarke, Bart L. ;
Clines, Gregory A. ;
Compston, Juliet E. ;
Drake, Matthew T. ;
Edwards, Beatrice J. ;
Favus, Murray J. ;
Greenspan, Susan L. ;
McKinney, Ross, Jr. ;
Pignolo, Robert J. ;
Sellmeyer, Deborah E. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (01) :16-35
[2]  
Aletaha D, UPCHURCH
[3]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[4]   Bisphosphonate therapy in rheumatoid arthritis [J].
Breuil, Veronique ;
Euller-Ziegler, Liana .
JOINT BONE SPINE, 2006, 73 (04) :349-354
[5]   Absence of femoral cortical thickening in long-term bisphosphonate users: Implications for atypical femur fractures [J].
Chen, Foster ;
Wang, Zhong ;
Bhattacharyya, Timothy .
BONE, 2014, 62 :64-66
[6]  
Di Munno O, 2004, J RHEUMATOL, V31, P1305
[7]   Incidence and demography of femur fractures with and without atypical features [J].
Feldstein, Adrianne C. ;
Black, Dennis ;
Perrin, Nancy ;
Rosales, A. Gabriela ;
Friess, Darin ;
Boardman, David ;
Dell, Richard ;
Santora, Arthur ;
Chandler, Julie M. ;
Rix, Mary M. ;
Orwoll, Eric .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (05) :977-986
[8]   Location of fractures and the characteristics of patients with atypical femoral fractures: analyses of 38 Japanese cases [J].
Hyodo, Kojiro ;
Nishino, Tomofumi ;
Kamada, Hiroshi ;
Nozawa, Daisuke ;
Mishima, Hajime ;
Yamazaki, Masashi .
JOURNAL OF BONE AND MINERAL METABOLISM, 2017, 35 (02) :209-214
[9]   Comparison of Disease Activity Score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values [J].
Inoue, Eisuke ;
Yamanaka, Hisashi ;
Hara, Masako ;
Tomatsu, Taisuke ;
Kamatani, Naoyuki .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (03) :407-409
[10]   Factors associated with atypical femoral fracture [J].
Kim, Dam ;
Sung, Yoon-Kyoung ;
Cho, Soo-Kyung ;
Han, Minkyung ;
Kim, Yee-Suk .
RHEUMATOLOGY INTERNATIONAL, 2016, 36 (01) :65-71